Author Archives: administrator

About administrator

University of Pittsburgh Research Assistant and Technical Writer

Neurological manifestations of HIV

Dr Faktorovich, Department of Neurology, Icahn School of Medicine, Mt Sinai, New York, NY

From Neurologytimes.com

Human immunodeficiency virus (HIV) is responsible for a wide spectrum of neurological manifestations, with etiologies ranging from inflammatory, infectious, neoplastic. and more. The development of antiretroviral therapy (ART) has dramatically increased life expectancy, however neurological complications remain a significant cause of long-term disability. Understanding and recognizing these conditions is crucial in effectively managing HIV.

Dr Svetlana Faktorovich, Department of Neurology, Icahn School of Medicine, explains the various forms of neurological manifestations of HIV in this Neurologytimes.com article.

Why STDs are on the rise in America

From the Economist online

Much of the increase in STDs has come from gay and bisexual men. Although a relatively small share of the population, they accounted for 81% of male syphilis cases in 2016, according to the Centres for Disease Control. As with heterosexuals, this seems to be because sex is now seen as less risky. That is due to the advent of PrEP, a prophylactic drug cocktail which gay men can take to nearly inoculate themselves from HIV. The reduced chances of catching HIV—along with the fact that a positive diagnosis is no longer a death sentence—seems to encourage men to drop their guard. A recent study of gay and bisexual men, published in the Lancet, a medical journal, found that as more began taking PrEP, rates of consistent condom usage dropped from 46% to 31%. Recent studies have shown that uptake of PrEP is strongly associated with increased rates of STD infection.

All this shows that changing sexual mores, and a reduced fear of the risks of unprotected sex, seem to be at fault—especially since the problem is not just limited to America. England experienced a 20% increase in syphilis diagnoses in 2017 and a 22% increase in those of gonorrhoea. Other countries in western Europe have seen ever worse outbreaks, sometimes exceeding 50%. Dwindling public spending on STD prevention—which in America has fallen by 40% in real terms since 2003—is not helping matters. Yet the chief methods of prevention, abstinence and condoms, are tried and true. Should these options seem too chaste or chaffing, then prospective partners ought to get an STD test (especially since most infections can be cleared up with a simple course of antibiotics). Verified testing is vital since verbal assurances, especially on the cusp of a liaison, can be misleading.

Read the full article.

CDC’s Eugene McCray discusses HIV prevention advances from AIDS 2018 in Amsterdam

Eugene McCray MD

From AIDS.gov

Advances in HIV prevention and program implementation were among the topics in the spotlight at the 22nd International AIDS Conference (AIDS 2018) this week. Eugene McCray, MD, Director of CDC’s Division of HIV/AIDS Prevention (DHAP)

reflects on some of the conference highlights. The division he oversees works to prevent HIV infections and reduce the incidence of HIV-related illness and death across the United States. Read more about their work.

During a live interview on Facebook, Dr. McCray discussed research being presented by CDC researchers at the conference, other HIV prevention research findings shared here at the conference, and shares his personal reflection on what how it feels like to be at this conference at this stage of the epidemic.

Watch the video.

New HIV research findings from AIDS 2018 with NIH’s Dr. Carl Dieffenbach

From AIDS.gov

The first full day of sessions at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam was filled with new scientific findings shared by researchers from around the world. In a Facebook Live interview with HIV.gov, Carl Dieffenbach, Ph.D., discussed highlights of three studies presented today at the conference, including:

  • an update on a potential association between the HIV treatment medication dolutegravir and birth defects;
  • additional research on the effectiveness of HIV treatment as prevention among gay male serodifferent couples; and
  • a study on whether there may be drug-drug interactions between PrEP and feminizing hormone therapy for transgender women.

Dr. Dieffenbach is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Watch the video here.

22nd International AIDS Conference (AIDS 2018) underway in Amsterdam

From HIV.gov

As the 22nd International AIDS Conference (AIDS 2018) got underway in Amsterdam, HIV.gov began their coverage of HIV research advances and other conference highlights with an interview of Anthony S. Fauci, M.D. Dr. Fauci is the Director of the National Institute of Allergy and Infectious Diseases at the NIH.

Interview of Anthony S. Fauci, M.D.

The International AIDS Conference is the largest conference on any global health issue in the world. First convened during the peak of the AIDS epidemic in 1985, it continues to provide a unique forum for the intersection of science, advocacy, and human rights. According to its organizers, each conference is an opportunity to strengthen policies and programs that ensure an evidence-based response to the epidemic.

The theme of AIDS 2018 is “Breaking Barriers, Building Bridges,” drawing attention to the need of rights-based approaches to more effectively reach key populations. AIDS 2018 aims to promote human rights based and evidence-informed HIV responses that are tailored to the needs of particularly vulnerable communities – including people living with HIV, displaced populations, men who have sex with men, people in prisons and other closed settings, people who use drugs, sex workers, transgender people, women and girls and young people – and collaborate in fighting the disease beyond country borders.

 

 

New report from UN warns we have ‘miles to go’ in fight against HIV

From ABC News

Rates of HIV infection are on the rise in 50 countries with more than 1.8 million people becoming infected in 2017, a far cry from goals established for the near future, according to a new United Nations report.

The report, entitled “Miles to Go,” published earlier this week by the Joint United Nations Program on HIV/AIDS, says the pace of progress in saving lives and preventing new infections is “not matching the global ambition” of cutting the infection rate to 500,000 a year by 2020.

While the death rate from AIDS-related illnesses — 940,000 in 2017 — is the lowest this century, it is still nearly double the goal of reducing AIDS-related deaths to 500,000 or fewer by 2020, according to the report.

”New HIV infections are not falling fast enough,” Michel Sidibé, UNAIDS Executive Director, wrote in the report. “HIV prevention services are not being provided on an adequate scale and with sufficient intensity and are not reaching the people who need them the most.”

Read the full article and see the video here.

How Truvada helped propel the evolution of LGBT health

From The Advocate online

In light of the progress we’ve made over the past decades, it’s tempting to think that we are only steps away from a cure and that our previous advances will protect younger LGBTQ people for generations. While it’s empowering to feel confident in our current position, it is essential that we remember that all of this is fragile. According to a recent statistic from the Centers for Disease Control and Prevention, HIV and AIDS remain persistent problems globally. We’ve come a long way in preventing and treating HIV, but there is still much more to accomplish. Annual HIV infections and diagnoses are declining in the U.S., but progress has been uneven, and annual infections and diagnoses have increased among some groups. The declines can thankfully be attributed to targeted HIV prevention efforts, such as Truvada.

Read the full article.